Amedeo Smart

Free Medical Literature Service

 

Amedeo

Rheumatoid Arthritis
  Free Subscription

Articles published in
Ann Rheum Dis
    September 2025
  1. SANTIAGO-LAMELAS L, Castro-Santos P, deAndres-Galiana EJ, Fernandez-Martinez JL, et al
    Identification of a novel transcriptome signature for predicting the response to anti-TNF-alpha treatment in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2025 Sep 3:S0003-4967(25)04302-X. doi: 10.1016/j.ard.2025.
    >> Share

  2. WILEY MM, Radziszewski M, Khatri B, Joachims ML, et al
    Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland.
    Ann Rheum Dis. 2025;84:1512-1527.
    >> Share

  3. BOUCLY A, Mitrovic S, Carmagnat M, Savale L, et al
    Pulmonary arterial hypertension in adults with Still's disease: another pulmonary manifestation associated with HLA-DRB1*15.
    Ann Rheum Dis. 2025;84:1538-1548.
    >> Share

    August 2025
  4. DE LIMA J, Boutet MA, Bortolotti O, Chepeaux LA, et al
    Spatial mapping of rheumatoid arthritis synovial niches reveals a LYVE1(+) macrophage network associated with response to therapy.
    Ann Rheum Dis. 2025 Aug 22:S0003-4967(25)04292-X. doi: 10.1016/j.ard.2025.
    >> Share

  5. GIOLLO A, Salvato M, Frizzera F, Khalid K, et al
    Clinical application of synovial biopsy in noninflammatory and persistent inflammatory refractory rheumatoid arthritis.
    Ann Rheum Dis. 2025 Aug 21:S0003-4967(25)04288-8. doi: 10.1016/j.ard.2025.
    >> Share

  6. TSALIKI M, Cavett J, Kurien BT, Bruxvoort C, et al
    A cross-sectional observational study of patients with sicca with salivary autoantibodies defines a potential new phenotype of Sjogren's disease.
    Ann Rheum Dis. 2025;84:1354-1362.
    >> Share

  7. KERSCHBAUMER A, Steiner M, Pruckner P, Wildner B, et al
    Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis.
    Ann Rheum Dis. 2025 Aug 1:S0003-4967(25)04243-8. doi: 10.1016/j.ard.2025.
    >> Share

    July 2025
  8. TRIAILLE C, Durez P, Smolen JS, McInnes IB, et al
    Precision medicine and the chaos theory in rheumatoid arthritis.
    Ann Rheum Dis. 2025 Jul 31:S0003-4967(25)04239-6. doi: 10.1016/j.ard.2025.
    >> Share

  9. WANG H, Nugteren S, Groenland RJ, van der Meulen S, et al
    Development of bispecific antibodies that drive selective targeted local complement inhibition on rheumatoid arthritis-related antigens.
    Ann Rheum Dis. 2025 Jul 18:S0003-4967(25)04183.
    >> Share

  10. BACKLUND R, Bergstrom U, Compagno M, Arvidsson L, et al
    Quantified intakes of key diet components and the risk of developing rheumatoid arthritis: Results from a nested case-control study.
    Ann Rheum Dis. 2025 Jul 10:S0003-4967(25)04175.
    >> Share

  11. BOWMAN SJ, Seror R, Porcher R, Arends S, et al
    Primary Sjogren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjogren's Syndrome: an Interventional Trial based on stratifYing patients (NECESS
    Ann Rheum Dis. 2025;84:1068-1089.
    >> Share

  12. MEUDEC L, Goudarzi N, Silva-Saffar SE, Pascaud J, et al
    Development of salivary gland organoids derived from patient biopsies: a functional model of Sjogren's disease.
    Ann Rheum Dis. 2025;84:1195-1206.
    >> Share

  13. PARODIS I, Lagutkin D, Lindblom J, Idborg H, et al
    New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
    Ann Rheum Dis. 2025;84:1180-1194.
    >> Share

    June 2025
  14. SCHAEFER M, Purschke A, Zietemann V, Rudi T, et al
    Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register.
    Ann Rheum Dis. 2025 Jun 25:S0003-4967(25)01024-6. doi: 10.1016/j.ard.2025.
    >> Share

  15. HECK C, Zimmermann-Geller B, Haun S, Lotfering F, et al
    Influence of canstatin on fibroblast-driven hypervascularisation in rheumatoid arthritis.
    Ann Rheum Dis. 2025 Jun 20:S0003-4967(25)01026-X. doi: 10.1016/j.ard.2025.
    >> Share

  16. BLOMBERG NJ, Kristyanto H, Verstappen M, Neppelenbroek S, et al
    Autoreactive B cells in extremes of rheumatoid arthritis disease phenotypes.
    Ann Rheum Dis. 2025 Jun 17:S0003-4967(25)00965-3. doi: 10.1016/j.ard.2025.
    >> Share

  17. JIN W, Wang Q, Jin C, Xue M, et al
    Spatiotemporal distributions and regional disparities of rheumatoid arthritis in 953 global to local locations, 1980-2040, with deep learning-empowered forecasts and evaluation of interventional policies' benefits.
    Ann Rheum Dis. 2025 Jun 12:S0003-4967(25)00898-2. doi: 10.1016/j.ard.2025.
    >> Share

  18. WINTHROP KL, Bathon J, Kerschbaumer A, Isaacs JD, et al
    Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024.
    Ann Rheum Dis. 2025;84:927-936.
    >> Share

    May 2025
  19. TAKANASHI S, Takeuchi T, Kaneko Y
    Prognosis of older patients with multimorbidity who do not meet the definition of difficult-to-treat rheumatoid arthritis but have uncontrolled disease activity.
    Ann Rheum Dis. 2025 May 29:S0003-4967(25)00963-X. doi: 10.1016/j.ard.2025.
    >> Share

  20. MARZEDA AM, Schwenzer A, Didov BS, Woolcock K, et al
    Investigating endogenous immune-mediated monocyte memory in rheumatoid arthritis.
    Ann Rheum Dis. 2025 May 10:S0003-4967(25)00883-0. doi: 10.1016/j.ard.2025.
    >> Share

  21. STEINZ N, Maarseveen TD, van den Akker EB, Cope AP, et al
    Time-independent disease state identification defines distinct trajectories determined by localised vs systemic inflammation in patients with early rheumatoid arthritis.
    Ann Rheum Dis. 2025 May 9:S0003-4967(25)00900-8. doi: 10.1016/j.ard.2025.
    >> Share

  22. HE Y, Sareila O, Johansson L, Agelii ML, et al
    Epitopes targeted by autoantibodies in presymptomatic individuals predict early rheumatoid arthritis.
    Ann Rheum Dis. 2025 May 9:S0003-4967(25)00902-1. doi: 10.1016/j.ard.2025.
    >> Share

  23. SHARMA SD, Hum RM, Nair N, Marshall L, et al
    Systematic review and independent validation of genetic factors of radiographic outcome in rheumatoid arthritis identifies a genome-wide association with CARD9.
    Ann Rheum Dis. 2025 May 8:S0003-4967(25)00897-0. doi: 10.1016/j.ard.2025.
    >> Share

  24. VAN STEENBERGEN HW, Doornkamp F, Alivernini S, Backlund J, et al
    EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia.
    Ann Rheum Dis. 2025 May 8:S0003-4967(25)00076-7. doi: 10.1016/j.ard.2025.
    >> Share

  25. WIENTJES MHM, Atiqi S, Wolbink GJ, Nurmohamed MT, et al
    Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial.
    Ann Rheum Dis. 2025 May 2:S0003-4967(25)00885-4. doi: 10.1016/j.ard.2025.
    >> Share

  26. JAJODIA A, Mishra A, Doni Jayavelu N, Lambert K, et al
    Functional dissection of noncoding variants associated with rheumatoid arthritis.
    Ann Rheum Dis. 2025 May 2:S0003-4967(25)00890-8. doi: 10.1016/j.ard.2025.
    >> Share

  27. NASH P, Kerschbaumer A, Konzett V, Aletaha D, et al
    Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update.
    Ann Rheum Dis. 2025;84:664-679.
    >> Share

  28. KONZETT V, Smolen JS, Nash P, Aletaha D, et al
    Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement.
    Ann Rheum Dis. 2025;84:680-696.
    >> Share

    April 2025
  29. PECHER AC, Hensen L, Schairer-Marquardt R, Kowarik M, et al
    Relapse after anti-CD19 CAR T-cell therapy in a patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantation.
    Ann Rheum Dis. 2025 Apr 30:S0003-4967(25)00886-6. doi: 10.1016/j.ard.2025.
    >> Share

  30. WEI X, Wei C, Lin H, Xie Y, et al
    Anticitrullinated caspase 14 peptide antibody is a novel biomarker for seronegative rheumatoid arthritis.
    Ann Rheum Dis. 2025 Apr 29:S0003-4967(25)00892-1. doi: 10.1016/j.ard.2025.
    >> Share

  31. HETLAND ML, Heiberg MS, Sokka-Isler T, Rudin A, et al
    Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and
    Ann Rheum Dis. 2025 Apr 4:S0003-4967(25)00819-2. doi: 10.1016/j.ard.2025.
    >> Share

  32. HAUSER B, Merriman A, Foley J, Golla J, et al
    Methotrexate continuation increases fracture risk in patients who sustained lower limb insufficiency fractures.
    Ann Rheum Dis. 2025;84:554-561.
    >> Share

  33. TRYPOSKIADIS K, Nayar S, Pucino V, Smith CG, et al
    Increasing the number of minor salivary glands from patients with Sjogren's disease improves the diagnostic and measurement precision of the histological focus score.
    Ann Rheum Dis. 2025;84:601-608.
    >> Share

  34. VAN DER HELM-VAN MIL AHM, Aletaha D
    How to treat undifferentiated arthritis today or tomorrow? A consideration of treatment recommendations in light of current evidence.
    Ann Rheum Dis. 2025;84:521-528.
    >> Share

  35. SEBBAG E, Molina-Collada J, Ndoye R, Aletaha D, et al
    Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
    Ann Rheum Dis. 2025;84:643-652.
    >> Share

    March 2025
  36. CHARLTON RA, Gates E, Coates LC, Galloway J, et al
    Diagnostic delay and less intensive therapy for people with psoriatic arthritis compared with rheumatoid arthritis: a study nested within an English and Welsh audit data set.
    Ann Rheum Dis. 2025 Mar 29:S0003-4967(25)00816-7. doi: 10.1016/j.ard.2025.
    >> Share

  37. COLETTO LA, van Steenbergen HW, Di Mario C, Gessi M, et al
    Minimally invasive retrieval and characterisation of tenosynovial tissue in rheumatoid arthritis: a novel approach to study at-risk, active, and remission stages.
    Ann Rheum Dis. 2025 Mar 26:S0003-4967(25)00242-0. doi: 10.1016/j.ard.2025.
    >> Share

  38. SIMON N, Rudjito R, Moll L, Sandor K, et al
    Characterisation of the antinociceptive effect of baricitinib in the collagen antibody-induced arthritis mouse model.
    Ann Rheum Dis. 2025;84:421-434.
    >> Share

    February 2025
  39. RAYENS E, Sy LS, Qian L, Wu J, et al
    Effectiveness and safety of the recombinant zoster vaccine in individuals >/=50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study.
    Ann Rheum Dis. 2025 Feb 19:S0003-4967(25)00199-2. doi: 10.1016/j.ard.2025.
    >> Share

  40. UCHIYAMA S, Ishikawa Y, Ikari K, Honda S, et al
    Mosaic loss of chromosome Y characterises late-onset rheumatoid arthritis and contrasting associations of polygenic risk score based on age at onset.
    Ann Rheum Dis. 2025 Feb 19:S0003-4967(25)00184-0. doi: 10.1016/j.ard.2025.
    >> Share

  41. MOLANDER V, Bower H, Frisell T, Askling J, et al
    Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritis.
    Ann Rheum Dis. 2025 Feb 17:S0003-4967(25)00075-5. doi: 10.1016/j.ard.2025.
    >> Share

  42. FRAZZEI G, Landewe RBM, Wagenaar C, van de Stadt LA, et al
    Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort.
    Ann Rheum Dis. 2025 Feb 15:S0003-4967(25)00195-5. doi: 10.1016/j.ard.2025.
    >> Share

  43. LIDAR M, Rimar D, David P, Jacoby E, et al
    CD-19 CAR-T cells for polyrefractory rheumatoid arthritis.
    Ann Rheum Dis. 2025;84:370-372.
    >> Share

  44. ZHENG L, Gu M, Li X, Hu X, et al
    ITGA5(+) synovial fibroblasts orchestrate proinflammatory niche formation by remodelling the local immune microenvironment in rheumatoid arthritis.
    Ann Rheum Dis. 2025;84:232-252.
    >> Share

  45. KRONZER VL, Williamson KA, Hayashi K, Atkinson EJ, et al
    Uncovering specific genetic-respiratory disease endotypes for rheumatoid arthritis risk.
    Ann Rheum Dis. 2025;84:221-231.
    >> Share

  46. KUBO S, Miyazaki Y, Nishino T, Fujita Y, et al
    Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness.
    Ann Rheum Dis. 2025;84:210-220.
    >> Share

  47. FUKUI S, Winkelmayer WC, Tedeschi SK, Marrugo J, et al
    Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study.
    Ann Rheum Dis. 2025;84:201-209.
    >> Share

  48. LIU J, Jiang Y, Zhang S, Liu S, et al
    Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial.
    Ann Rheum Dis. 2025;84:188-200.
    >> Share

  49. BAKER KF, Spierings J, Brom M, Radstake T, et al
    Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration.
    Ann Rheum Dis. 2025;84:153-157.
    >> Share

    January 2025
  50. SCHER JU, Nayak R, Clemente JC
    Microbiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs.
    Ann Rheum Dis. 2025;84:9-13.
    >> Share

  51. VAN MULLIGEN E, Bour SS, Goossens LMA, de Jong PHP, et al
    Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial.
    Ann Rheum Dis. 2025;84:68-76.
    >> Share

  52. RUYSSEN-WITRAND A, Brusq C, Masson M, Bongard V, et al
    Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial.
    Ann Rheum Dis. 2025;84:49-59.
    >> Share

  53. TAMAI H, Ikeda K, Miyamoto T, Taguchi H, et al
    Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial.
    Ann Rheum Dis. 2025;84:41-48.
    >> Share

  54. DEANE KD, Holers VM, Emery P, Mankia K, et al
    Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease.
    Ann Rheum Dis. 2025;84:14-28.
    >> Share

    November 2024
  55. LIDAR M, Rimar D, David P, Jacoby E, et al
    CD-19 CAR-T cells for polyrefractory rheumatoid arthritis.
    Ann Rheum Dis. 2024 Nov 27:ard-2024-226437. doi: 10.1136/ard-2024-226437.
    >> Share

  56. LIU J, Jiang Y, Zhang S, Liu S, et al
    Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial.
    Ann Rheum Dis. 2024 Nov 27:ard-2024-226385. doi: 10.1136/ard-2024-226385.
    >> Share

  57. FAUTREL B, Mitrovic S, De Matteis A, Bindoli S, et al
    EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease.
    Ann Rheum Dis. 2024;83:1614-1627.
    >> Share

  58. BINDOLI S, De Matteis A, Mitrovic S, Fautrel B, et al
    Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.
    Ann Rheum Dis. 2024;83:1731-1747.
    >> Share

  59. DE MATTEIS A, Bindoli S, De Benedetti F, Carmona L, et al
    Systemic juvenile idiopathic arthritis and adult-onset Still's disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still's disease.
    Ann Rheum Dis. 2024;83:1748-1761.
    >> Share

  60. KACHLER K, Andreev D, Thapa S, Royzman D, et al
    Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis.
    Ann Rheum Dis. 2024;83:1691-1706.
    >> Share


  61. Correction: AB0159 Health related quality of life among patients with rheumatoid arthritis at Tikur Anbessa specialized Hospital. A Hospital- based cross sectional study.
    Ann Rheum Dis. 2024;83:e28.
    >> Share

  62. BAKER KF, Spierings J, Brom M, Radstake T, et al
    Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration.
    Ann Rheum Dis. 2024 Nov 12:ard-2024-226772. doi: 10.1136/ard-2024-226772.
    >> Share

  63. VENKEN K, Jarlborg M, Stevenaert F, Malfait TLA, et al
    Shared lung and joint T cell repertoire in early rheumatoid arthritis driven by cigarette smoking.
    Ann Rheum Dis. 2024 Nov 8:ard-2024-226284. doi: 10.1136/ard-2024-226284.
    >> Share

  64. ROONEY CM, Jeffery IB, Mankia K, Wilcox MH, et al
    Dynamics of the gut microbiome in individuals at risk of rheumatoid arthritis: a cross-sectional and longitudinal observational study.
    Ann Rheum Dis. 2024 Nov 8:ard-2024-226362. doi: 10.1136/ard-2024-226362.
    >> Share

  65. KRONZER VL, Williamson KA, Hayashi K, Atkinson EJ, et al
    Uncovering specific genetic-respiratory disease endotypes for rheumatoid arthritis risk.
    Ann Rheum Dis. 2024 Nov 1:ard-2024-226391. doi: 10.1136/ard-2024-226391.
    >> Share

  66. ZHENG L, Gu M, Li X, Hu X, et al
    ITGA5(+) synovial fibroblasts orchestrate proinflammatory niche formation by remodelling the local immune microenvironment in rheumatoid arthritis.
    Ann Rheum Dis. 2024 Nov 1:ard-2024-225778. doi: 10.1136/ard-2024-225778.
    >> Share

    October 2024
  67. RUYSSEN-WITRAND A, Brusq C, Masson M, Bongard V, et al
    Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo-controlled, double-blind trial.
    Ann Rheum Dis. 2024 Oct 29:ard-2024-226620. doi: 10.1136/ard-2024-226620.
    >> Share


  68. Correction: Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy.
    Ann Rheum Dis. 2024;83:e27.
    >> Share

  69. FEIST E, Fleischmann RM, Fatenejad S, Bukhanova D, et al
    Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.
    Ann Rheum Dis. 2024;83:1454-1464.
    >> Share

  70. KUBO S, Miyazaki Y, Nishino T, Fujita Y, et al
    Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness.
    Ann Rheum Dis. 2024 Oct 4:ard-2024-226228. doi: 10.1136/ard-2024-226228.
    >> Share

  71. TAMAI H, Ikeda K, Miyamoto T, Taguchi H, et al
    Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial.
    Ann Rheum Dis. 2024 Oct 4:ard-2024-226350. doi: 10.1136/ard-2024-226350.
    >> Share

    September 2024
  72. MAURO D, Lin X, Pontarini E, Wehr P, et al
    CD8(+) tissue-resident memory T cells are expanded in primary Sjogren's disease and can be therapeutically targeted by CD103 blockade.
    Ann Rheum Dis. 2024;83:1345-1357.
    >> Share

  73. HOFFMANN MH, Kirchner H, Kronke G, Riemekasten G, et al
    Inflammatory tissue priming: novel insights and therapeutic opportunities for inflammatory rheumatic diseases.
    Ann Rheum Dis. 2024;83:1233-1253.
    >> Share

  74. VAN MULLIGEN E, Bour SS, Goossens LMA, de Jong PHP, et al
    Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial.
    Ann Rheum Dis. 2024 Sep 18:ard-2024-226286. doi: 10.1136/ard-2024-226286.
    >> Share

  75. DEANE KD, Holers VM, Emery P, Mankia K, et al
    Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease.
    Ann Rheum Dis. 2024 Sep 6:ard-2023-224211. doi: 10.1136/ard-2023-224211.
    >> Share

  76. QIU F, Xie D, Chen H, Wang Z, et al
    Generation of cytotoxic aptamers specifically targeting fibroblast-like synoviocytes by CSCT-SELEX for treatment of rheumatoid arthritis.
    Ann Rheum Dis. 2024 Sep 4:ard-2024-225565. doi: 10.1136/ard-2024-225565.
    >> Share

    August 2024
  77. PARKER M, Zheng Z, Lasarev MR, Larsen MC, et al
    Novel autoantibodies help diagnose anti-SSA antibody negative Sjogren disease and predict abnormal labial salivary gland pathology.
    Ann Rheum Dis. 2024;83:1169-1180.
    >> Share

  78. KHIDIR SJH, Toes REM, van Mulligen E, van der Helm-van Mil AHM, et al
    Is tooth extraction as proxy for periodontal disease related to the development of RA? Lessons from a longitudinal study in the at-risk stage of clinically suspect arthralgia.
    Ann Rheum Dis. 2024;83:1227-1229.
    >> Share

  79. FUKUI S, Winkelmayer WC, Tedeschi SK, Marrugo J, et al
    Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study.
    Ann Rheum Dis. 2024 Aug 21:ard-2024-226156. doi: 10.1136/ard-2024-226156.
    >> Share

  80. TU J, Chen W, Huang W, Wang X, et al
    Positive feedback loop PU.1-IL9 in Th9 promotes rheumatoid arthritis development.
    Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. doi: 10.1136/ard-2024-226067.
    >> Share

  81. WU H, Yuan H, Zhang J, He T, et al
    Helicobacter pylori upregulates PAD4 expression via stabilising HIF-1alpha to exacerbate rheumatoid arthritis.
    Ann Rheum Dis. 2024 Aug 6:ard-2023-225306. doi: 10.1136/ard-2023-225306.
    >> Share

    July 2024
  82. HU F, Li X, Liu K, Li Y, et al
    Rheumatoid arthritis patients harbour aberrant enteric bacteriophages with autoimmunity-provoking potential: a paired sibling study.
    Ann Rheum Dis. 2024 Jul 31:ard-2024-225564. doi: 10.1136/ard-2024-225564.
    >> Share

  83. LEND K, Lampa J, Padyukov L, Hetland ML, et al
    Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial.
    Ann Rheum Dis. 2024 Jul 30:ard-2024-226024. doi: 10.1136/ard-2024-226024.
    >> Share

  84. VAN MULLIGEN E, Rutten-van Molken M, van der Helm-van Mil A
    Early identification of rheumatoid arthritis: does it induce treatment-related cost savings?
    Ann Rheum Dis. 2024 Jul 17:ard-2024-225746. doi: 10.1136/ard-2024-225746.
    >> Share

  85. GENTE K, Feisst M, Marx D, Klika KD, et al
    Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease.
    Ann Rheum Dis. 2024;83:974-983.
    >> Share

  86. GUPTA S, Yamada E, Nakamura H, Perez P, et al
    Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjogren's disease.
    Ann Rheum Dis. 2024;83:1034-1047.
    >> Share

  87. YOSHIMURA Y, Yamanouchi M, Mizuno H, Ikuma D, et al
    Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease.
    Ann Rheum Dis. 2024 Jul 4:ard-2024-225914. doi: 10.1136/ard-2024-225914.
    >> Share

    June 2024
  88. HAGHIKIA A, Hegelmaier T, Wolleschak D, Bottcher M, et al
    Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis.
    Ann Rheum Dis. 2024 Jun 27:ard-2024-226017. doi: 10.1136/ard-2024-226017.
    >> Share

    May 2024
  89. BAERWALD C, Stemmler E, Gnuchtel S, Jeromin K, et al
    Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of pain.
    Ann Rheum Dis. 2024 May 30:ard-2023-225414. doi: 10.1136/ard-2023-225414.
    >> Share

  90. PISANIELLO HL, Lester SE, Russell O, Black R, et al
    The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD).
    Ann Rheum Dis. 2024 May 29:ard-2024-225696. doi: 10.1136/ard-2024-225696.
    >> Share

  91. BURMESTER GR, Gottenberg JE, Caporali R, Winthrop KL, et al
    Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years.
    Ann Rheum Dis. 2024 May 23:ard-2024-225759. doi: 10.1136/ard-2024-225759.
    >> Share

  92. LAGE-HANSEN PR, Svendsen N, Kirkham J, Nielsen SM, et al
    Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set.
    Ann Rheum Dis. 2024 May 22:ard-2024-225523. doi: 10.1136/ard-2024-225523.
    >> Share

  93. BECKMANN D, Krause A, Hansen U, Kiener HP, et al
    Focal adhesion protein Lasp1 links the Arp2/3 complex to adherens junctions and promotes motility of arthritic fibroblast-like synoviocytes.
    Ann Rheum Dis. 2024;83:816-819.
    >> Share

  94. LIU D, Kuang Y, Chen S, Li R, et al
    NAT10 promotes synovial aggression by increasing the stability and translation of N4-acetylated PTX3 mRNA in rheumatoid arthritis.
    Ann Rheum Dis. 2024 May 8:ard-2023-225343. doi: 10.1136/ard-2023-225343.
    >> Share

    April 2024
  95. IKDAHL E, Semb AG, Kerola AM
    No sign of elevated cardiovascular risk in patients with seropositive rheumatoid arthritis who remain on stable antirheumatic therapy: results from the nationwide Norwegian Cardio-Rheuma Register.
    Ann Rheum Dis. 2024 Apr 23:ard-2024-225758. doi: 10.1136/ard-2024-225758.
    >> Share

  96. LUO X, Ren Y, Chen Y
    Gender imbalance in expert panels of recommendations in rheumatology.
    Ann Rheum Dis. 2024;83:682-684.
    >> Share

  97. HERNANDEZ-CRUZ B, Otero-Varela L, Freire-Gonzalez M, Busquets-Perez N, et al
    Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
    Ann Rheum Dis. 2024 Apr 9:ard-2023-225271. doi: 10.1136/ard-2023-225271.
    >> Share

    March 2024
  98. COHEN P, Ziff D, Lipsky PE
    Morris Ziff.
    Ann Rheum Dis. 2024;83:417-420.
    >> Share

  99. WINTHROP KL, Mease P, Kerschbaumer A, Voll RE, et al
    Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.
    Ann Rheum Dis. 2024;83:409-416.
    >> Share

  100. MELOKHINA V, Paulshus Sundlisaeter N, Sexton J, Sundin U, et al
    Subclinical inflammation and joint damage progression in patients with early RA fulfilling 2011 vs 2022 ACR/EULAR Boolean remission criteria: data from the ARCTIC study.
    Ann Rheum Dis. 2024;83:540-541.
    >> Share

    February 2024
  101. HE Y, Aoun M, Xu Z, Holmdahl R, et al
    Shift in perspective: autoimmunity protecting against rheumatoid arthritis.
    Ann Rheum Dis. 2024 Feb 27:ard-2023-225237. doi: 10.1136/ard-2023-225237.
    >> Share

  102. VAN DER WOUDE D, Toes REM
    Immune response to post-translationally modified proteins in rheumatoid arthritis: what makes it special?
    Ann Rheum Dis. 2024 Feb 20:ard-2023-224103. doi: 10.1136/ard-2023-224103.
    >> Share


  103. Correction: Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study.
    Ann Rheum Dis. 2024;83:e8.
    >> Share


  104. Correction: A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis.
    Ann Rheum Dis. 2024;83:e9.
    >> Share

  105. TANG Z, Shi H, Liu HL, Cheng X, et al
    Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria'.
    Ann Rheum Dis. 2024;83:e4.
    >> Share

  106. BARBHAIYA M, Zuily S, Hendry AM, Manneville F, et al
    Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Tang et al.
    Ann Rheum Dis. 2024;83:e5.
    >> Share

  107. DAMOISEAUX J, van Beers J
    Correspondence on "ACR/EULAR antiphospholipid syndrome classification criteria".
    Ann Rheum Dis. 2024;83:e6.
    >> Share

  108. ERKAN D, Barbhaiya M, Zuily S, Bertolaccini ML, et al
    Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Miro-Mur et al.
    Ann Rheum Dis. 2024;83:e3.
    >> Share

  109. BARBHAIYA M, Zuily S, Bertolaccini ML, Willis R, et al
    Response to: Correspondence on 'ACR/EULAR antiphospholipid syndrome classification criteria' by Damoiseaux and van Beers.
    Ann Rheum Dis. 2024;83:e7.
    >> Share

  110. MIRO-MUR FA, Alijotas-Reig J, Anunciacion-Llunell A, Marques-Soares J, et al
    Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria'.
    Ann Rheum Dis. 2024;83:e2.
    >> Share

  111. PEZOT M, Nocturne G, Belkhir R, Henry J, et al
    Obinutuzumab in patients with Sjogren's disease immunised against rituximab.
    Ann Rheum Dis. 2024;83:407-408.
    >> Share

  112. DORNER T, Kaul M, Szanto A, Tseng JC, et al
    Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
    Ann Rheum Dis. 2024;83:360-371.
    >> Share

  113. CROWSON CS, Atkinson EJ, Kronzer VL, Kimbrough BA, et al
    Comorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis.
    Ann Rheum Dis. 2024 Feb 8:ard-2023-225093. doi: 10.1136/ard-2023-225093.
    >> Share

  114. SCHENNING LCM, Ottevanger R, Quint KD, Tas SW, et al
    An ulcerating skin tumour in a patient with rheumatoid arthritis.
    Ann Rheum Dis. 2024 Feb 5:ard-2023-225436. doi: 10.1136/ard-2023-225436.
    >> Share

  115. HU F, Shi L, Liu X, Chen Y, et al
    Proinflammatory phenotype of B10 and B10pro cells elicited by TNF-alpha in rheumatoid arthritis.
    Ann Rheum Dis. 2024 Feb 1:ard-2023-224878. doi: 10.1136/ard-2023-224878.
    >> Share

    January 2024
  116. WU G, Cao B, Zhai H, Liu B, et al
    EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3.
    Ann Rheum Dis. 2024 Jan 25:ard-2023-224852. doi: 10.1136/ard-2023-224852.
    >> Share

  117. HECKERT SL, Maassen JM, le Cessie S, Goekoop-Ruiterman YPM, et al
    Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort.
    Ann Rheum Dis. 2024;83:161-168.
    >> Share

  118. BONELLI M, Kerschbaumer A, Kastrati K, Ghoreschi K, et al
    Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
    Ann Rheum Dis. 2024;83:139-160.
    >> Share

  119. TANAKA H, Okada Y, Nakayamada S, Miyazaki Y, et al
    Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping.
    Ann Rheum Dis. 2024;83:242-252.
    >> Share

  120. DREHER M, Witte T, Hoeper K, Assmann G, et al
    Rheuma-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres.
    Ann Rheum Dis. 2024;83:184-193.
    >> Share

  121. SCHIFF AE, Wang X, Patel NJ, Kawano Y, et al
    Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study.
    Ann Rheum Dis. 2024 Jan 10:ard-2023-225162. doi: 10.1136/ard-2023-225162.
    >> Share

  122. AVOUAC J, Hecquet S, Thomas M, Combier A, et al
    Validation of the definition of rheumatoid arthritis flare based on SDAI and CDAI in clinical practice in two French independent cohorts.
    Ann Rheum Dis. 2024 Jan 5:ard-2023-225272. doi: 10.1136/ard-2023-225272.
    >> Share

  123. TEUWEN MMH, van Weely SFE, Vliet Vlieland TPM, van Wissen MAT, et al
    Effectiveness of longstanding exercise therapy compared with usual care for people with rheumatoid arthritis and severe functional limitations: a randomised controlled trial.
    Ann Rheum Dis. 2024 Jan 3:ard-2023-224912. doi: 10.1136/ard-2023-224912.
    >> Share

  124. BAKER JF, ODell JR, England BR, Giles JT, et al
    Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis.
    Ann Rheum Dis. 2024 Jan 3:ard-2023-225014. doi: 10.1136/ard-2023-225014.
    >> Share


  125. Correction: Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
    Ann Rheum Dis. 2024;83:e1.
    >> Share

  126. CAO S, Li Y, Song R, Meng X, et al
    L-arginine metabolism inhibits arthritis and inflammatory bone loss.
    Ann Rheum Dis. 2024;83:72-87.
    >> Share

  127. BIJLSMA JWJ
    Annals of the Rheumatic Diseases collection on glucocorticoids (2020-2023): novel insights and advances in therapy.
    Ann Rheum Dis. 2024;83:4-8.
    >> Share

  128. BERRY JS, Tarn J, Casement J, Duret PM, et al
    Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis.
    Ann Rheum Dis. 2024;83:88-95.
    >> Share

    December 2023
  129. AYMON R, Mongin D, Bergstra SA, Choquette D, et al
    Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
    Ann Rheum Dis. 2023 Dec 8:ard-2023-224670. doi: 10.1136/ard-2023-224670.
    >> Share

  130. TRIAILLE C, Tilman G, Sokolova T, Loriot A, et al
    Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis.
    Ann Rheum Dis. 2023;82:1538-1546.
    >> Share

  131. YAMADA H, Haraguchi A, Tsuru T, Kondo M, et al
    Low avidity observed for anti-citrullinated peptide antibody is not a general phenomenon for autoantibodies.
    Ann Rheum Dis. 2023;82:1637-1638.
    >> Share

    November 2023
  132. LIEN HJT, Pedersen TT, Jakobsen B, Flatberg A, et al
    Single-cell resolution of longitudinal blood transcriptome profiles in rheumatoid arthritis, systemic lupus erythematosus and healthy control pregnancies.
    Ann Rheum Dis. 2023 Nov 30:ard-2023-224644. doi: 10.1136/ard-2023-224644.
    >> Share

  133. PERTSINIDOU E, Saevarsdottir S, Manivel VA, Klareskog L, et al
    In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation.
    Ann Rheum Dis. 2023 Nov 27:ard-2023-224728. doi: 10.1136/ard-2023-224728.
    >> Share

  134. MOULIN D, Millard M, Taieb M, Michaudel C, et al
    Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis.
    Ann Rheum Dis. 2023 Nov 24:ard-2023-224014. doi: 10.1136/ard-2023-224014.
    >> Share

  135. GOLDMANN K, Spiliopoulou A, Iakovliev A, Plant D, et al
    Expression quantitative trait loci analysis in rheumatoid arthritis identifies tissue specific variants associated with severity and outcome.
    Ann Rheum Dis. 2023 Nov 18:ard-2023-224540. doi: 10.1136/ard-2023-224540.
    >> Share

  136. SIMON TA, Dong L, Suissa S, Michaud K, et al
    Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies.
    Ann Rheum Dis. 2023 Nov 6:ard-2023-224356. doi: 10.1136/ard-2023-224356.
    >> Share


  137. Correction: Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis.
    Ann Rheum Dis. 2023;82:e227.
    >> Share


  138. Correction: Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
    Ann Rheum Dis. 2023;82:e222.
    >> Share

  139. WOLLHEIM FA
    Nanna Svartz (1890-1986) and the discovery of sulfasalazine.
    Ann Rheum Dis. 2023;82:1382-1386.
    >> Share

  140. SAVIANO A, Manosour AA, Raucci F, Merlino F, et al
    New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function.
    Ann Rheum Dis. 2023;82:1415-1428.
    >> Share

  141. SCHERLINGER M, Schaeverbeke T
    Correspondence on 'Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting'.
    Ann Rheum Dis. 2023;82:e221.
    >> Share

  142. OZEN G, Pedro S, Michaud K
    Major adverse cardiovascular events and mortality with opioids versus NSAIDs initiation in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2023;82:1487-1494.
    >> Share

    October 2023
  143. WESTHOVENS R, Verschueren P
    Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023.
    Ann Rheum Dis. 2023 Oct 30:ard-2023-224904. doi: 10.1136/ard-2023-224904.
    >> Share

  144. KONZETT V, Kerschbaumer A, Smolen JS, Kristianslund EK, et al
    Definition of rheumatoid arthritis flare based on SDAI and CDAI.
    Ann Rheum Dis. 2023 Oct 27:ard-2023-224742. doi: 10.1136/ard-2023-224742.
    >> Share

  145. VAN WESEMAEL TJ, Reijm S, Kawakami A, Dorjee AL, et al
    IgM antibodies against acetylated proteins as a possible starting point of the anti-modified protein antibody response in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Oct 3:ard-2023-224553. doi: 10.1136/ard-2023-224553.
    >> Share


  146. Correction: Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial.
    Ann Rheum Dis. 2023;82:e219.
    >> Share

  147. VAN MULLIGEN E, van der Helm-van Mil A, de Jong PHP
    Methotrexate prolongs TNF inhibitor survival, but only in autoantibody-positive rheumatoid arthritis: a validation study.
    Ann Rheum Dis. 2023;82:e217.
    >> Share

  148. MA KS, Chiang CH, Chen YW, Wang LT, et al
    Correspondence to 'Bacterial citrullinated epitopes generated by Porphyromonas gingivalis infection-a missing link for ACPA production'.
    Ann Rheum Dis. 2023;82:e216.
    >> Share

    September 2023
  149. KONZETT V, Kerschbaumer A, Smolen JS, Aletaha D, et al
    Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Sep 27:ard-2023-224477. doi: 10.1136/ard-2023-224477.
    >> Share

  150. FLEISCHMANN RM, van der Heijde D, Strand V, Atsumi T, et al
    Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
    Ann Rheum Dis. 2023 Sep 12:ard-2023-224482. doi: 10.1136/ard-2023-224482.
    >> Share

  151. YAP CF, Nair N, de Vries A, Loeff FC, et al
    HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2023 Sep 12:ard-2023-223955. doi: 10.1136/ard-2023-223955.
    >> Share

  152. TAYLOR PC, Weinblatt ME, McInnes IB, Atsumi T, et al
    Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
    Ann Rheum Dis. 2023 Sep 11:ard-2023-224449. doi: 10.1136/ard-2023-224449.
    >> Share

    April 2023
  153. MEYER A, Sienes RE, Nijim W, Zanotti B, et al
    Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells.
    Ann Rheum Dis. 2023;82:483-495.
    >> Share

  154. REUTER K, Rocca E
    Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e91.
    >> Share

  155. ZHENG BK
    Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
    Ann Rheum Dis. 2023;82:e93.
    >> Share

  156. GEORGIADIS AN, Pelechas E, Voulgari PV, Drosos AA, et al
    Correspondence on 'Cardiovascular effects of biological versus csDMARD therapy in treatment naive, early rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e89.
    >> Share

  157. PLEIN S, Buch MH
    Response to: 'Correspondence on 'Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis'' by Georgiadis et al.
    Ann Rheum Dis. 2023;82:e90.
    >> Share

  158. ABTAHI S, Driessen JHM, Burden AM, Souverein PC, et al
    Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'' by Zheng.
    Ann Rheum Dis. 2023;82:e94.
    >> Share

  159. ZERVOU MI, Goulielmos GN
    Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden'.
    Ann Rheum Dis. 2023;82:e87.
    >> Share

  160. CONRAD N, McInnes IB, Mcmurray JJV, Sattar N, et al
    Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management?
    Ann Rheum Dis. 2023;82:457-459.
    >> Share

  161. SHARMA C, Whittle S, Haghighi PD, Burstein F, et al
    Response to 'Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'' by Reuter et al.
    Ann Rheum Dis. 2023;82:e92.
    >> Share

  162. MOLANDER V, Askling J
    Response to: 'Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden'' by Zervou et al.
    Ann Rheum Dis. 2023;82:e88.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016